Canadian AIDS Society announces Innovative Cannabis Research Program Funded by Canopy Growth Corporation

OTTAWA, July 6, 2017 /CNW/ - The Canadian AIDS Society announced today a first of its kind research program funded by Canopy Growth Corporation. The program is designed to provide up-to-date information on the current state of evidence and research pertaining to the use of cannabis for medical purposes and to build tools for healthcare professionals to allow them to confidently assess and prescribe cannabis to appropriate patients.

Funded over two years at $100,000 per year by Canopy Growth Corporation — and guided by a newly created Cannabis Research Task Force of experts in the field of cannabinoid medicine — the project aims to develop guidelines and recommendations regarding the medical use of cannabis for optimal wellness, quality of life and pain management.

"Our goal is to leverage our existing knowledge and expertise in both HIV and the use of cannabis for medical purposes to create a better quality of life for many Canadians facing debilitating health conditions — particularly in the area of chronic pain management," said Gary Lacasse, Executive Director of the Canadian AIDS Society. "This project builds on a body of existing knowledge and research developed by CAS over several years."

The Task Force will be addressing issues surrounding the current lack of information — for Canadian health care practitioners and ultimately for patients — regarding guidance on the use of cannabis for medical or therapeutic purposes. It is estimated that 10% of Canadian physicians have written an authorization for medical cannabis.

"We are confident that this partnership with the Canadian AIDS Society and the broad medical and social expertise of the Task Force will result in practical guidelines for the use of cannabis that can be applied to many medical conditions," said Mark Zekulin, President, Canopy Growth Corporation. "We have dedicated a great deal of effort toward physician education over the last three years and I feel confident that this work will create another valuable tool that Canadian healthcare professionals and Canadians alike can use when considering cannabis as a therapy.."

The Cannabis Research Task Force is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.

Fact Sheet
Cannabis Research Program
Funded by Canopy Growth Corporation

In Canada, approximately 75,500 are living with HIV and about 250,000 are living with hepatitis C (HCV).

Cannabis has been proven to be effective to relieve symptoms — including chronic pain management — related to many medical conditions.

The Cannabis Research Task Force brought together by the Canadian AIDS Society is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.

As of July 6, 2017, the members of the Cannabis Research Task Force include:

Name

Organization/Population

Shari Margolese

Community Research Consultant

Danial Schecter

MD and medical director,

Canadian Cannabinoid Medical Clinic

Janet Yale

CEO, The Arthritis Society

Enrico Mandarino

Community Research Consultant and healthcare professional

Alan Bell

Family physician and clinical researcher

Caroline MacCallum

Internist / Clinical Instructor and Medical Director of

Greenleaf Medical Clinic

Paul Daeninck

Medical oncologist

Jonathan Zaid

Executive Director,

Canadians for Fair Access to Medical Marijuana

Lynne Belle-Isle

National Program Manager, CAS

Liz Christie

National Program Manager, CAS

Gary Lacasse

Executive Director, CAS

Hilary Black

Canopy Growth Corporation **Ex officio**

About the Canadian AIDS Society (CAS)
The Canadian AIDS Society (CAS) is a national coalition of community-based AIDS organizations across Canada. CAS is dedicated to strengthening the response to HIV/AIDS across all sectors of society, and to enriching the lives of people and communities living with, or affected by, HIV/AIDS. For more information, please visit www.cdnaids.ca.

About Canopy Growth Corporation (CGC)
Canopy Growth is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of GMP-certified indoor and greenhouse production capacity, all to an unparalleled level of quality assurance procedures and testing. Canopy Growth has established partnerships with leading sector names in Canada and abroad, with interests and operations spanning four continents. The Company is proudly dedicated to educating healthcare practitioners, providing consistent access to high-quality cannabis products, conducting robust clinical research, and furthering the public's understanding of cannabis. For more information visit www.canopygrowth.com.

NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc., Mettrum Health Corp., or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Canopy Growth Corporation

For further information: For media enquiries: Janne Charbonneau, Communications & National Programs, Canadian AIDS Society, (613) 230-3580 extension 130, janne.charbonneau@cdnaids.ca; Jordan Sinclair, Director of Communications, Canopy Growth Corporation, 613-769-4196, Jordan@canopygrowth.com

RELATED LINKS
http://canopygrowth.com/
http://www.cdnaids.ca

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890